Vaccinations are the most important preventive measure against infectious diseases
Not only do infections like measles and human papilloma virus (HPV) have a poor prognosis, they can also cause other diseases as a complication. The background of this argument is on the one hand the trust of parents in state of the art medicine and on the other hand less public awareness of complications of the infection. Measles has the following complications: otitis media, pneumonia, postinfectious encephalomyelitis, SSPE and sustainable immunosuppression [
42,
43]. The mortality of measles nowadays is 1 in 1000 cases in industrialized countries. The two most severe complications are SSPE and sustainable immunosuppression. SSPE has an incidence of 1 in 5000–10,000 but is even more common when infection occurs in the first year of life (1:600). The reason why SSPE is a dangerous complication is because there is no cure and it will inevitably lead to death. Herd immunity is necessary to protect from SSPE. When measles was eliminated from the USA, SSPE decreased to zero for children born in the USA.
Sustainable immunosuppression is caused by the continuous destruction of memory cells. It increases the risk of being infected and dying from other non-targeted diseases [
44].
The most common sexually transmitted disease is HPV. There are low-risk and high-risk virus types. The low-risk types are not carcinogenic but can lead to genital warts. The high-risk types are carcinogenic [
45‐
47]. A persistent infection can lead in 10% of cases to cancer of the cervix, vulva, anus, penis and oropharynx. Cervical cancer in particular has a high incidence and >95% are caused by HPV. A meta-analysis has shown that in high income countries 5–8 years after HPV vaccination the prevalence of HPV 16 and 18 decreased by 83% in girls aged 13–19 years [
48]. HPV vaccines are highly effective and prevention is the better choice over treatment.
In general, beyond the age of compulsory school attendance, all vaccines have to be paid for privately at pharmacy prices.
In Germany statutory health insurance covers 90% of insured persons. The Robert Koch Institute (RKI) states about vaccine costs: of nearly 194 billion € spent by insurance companies in 2014, 33 billion (17%) were spent on medicinal products and only a little over 1 billion € (0.65%) was spent on vaccines; however, normal medicinal products have to be given frequently (e.g. insulin) whereas vaccines are needed infrequently (such as MMR twice over a person’s life). Since production of vaccines is costly and complex [
49], there are only a handful of vaccine producers worldwide.
With few exceptions, most vaccines are cost-saving, particularly when also considering the additional indirect protection of unvaccinated people due to herd immunity. For economic assessment the term number needed to vaccinate to prevent one case/one hospitalization/one death (NNV) is used. In this connection only the vaccinated group is calculated, but not other age groups who are indirectly protected due to reduced frequency of infection or herd immunity.
The driving force behind infection through influenza is children <6 years. They can infect others (grandparents!), therefore by vaccinating children, older age groups have a reduced risk of infection [
50].
Although in oncology physicians cannot be responsible for prices of anti-cancer drugs, the benefit of new anti-cancer drugs may only last some months, but for a high price. As an example, the treatment of late-stage colorectal cancer with bevacizumab has a price tag of 50,000 $ per treatment episode, but only a benefit of incremental increase of life expectancy of 5 months. On average 9 treatment episodes are necessary [
51].
Prevention programs may provide a cost saving. But what is the price? In road safety in the EU a fatality avoided by introducing safety measures was worth 1 million € (the one million € rule introduced by the European Commission in 1997 based on calculations of 1995). Two improvements were made, resulting in acceptable costs per fatality avoided of 4.05 million €—this results in acceptable costs of about 5 million € nowadays [
52]. In contrast, to avoid one fatality from cervical cancer, only 101 girls (aged 9–14 years) need to be immunized with HPV vaccines. Assuming tender prices of 55 €/dose and a two-dose regimen, costs are less than 11,100 € to avoid one female death caused by HPV [
53]; however, in Austria the recommendation is to immunize boys and girls: a whole birth cohort (
n ~ 80,000) has therefore to be vaccinated with costs of about 8,800,000 € to reach the prevention optimum, including genital warts and male cancer. About 300 women die each year from cervical cancer [
54], so one can make a rough estimate of vaccine costs of 30,000 € to prevent one woman’s death from oncogenic HPV. Hence this is significantly cheaper than costs of death prevention in road traffic accidents.
A gender aspect can be also discussed since about 74% of deaths in road traffic are men but 100% of cervical carcinoma occur in women.
Each licensed vaccine is required to have a positive benefit-risk ratio. As an example, the risk of death from measles in industrialized countries with intensive care units is 1:1000 measles cases. The incidence of febrile seizures can be as high as 8% and can develop into encephalitis (1–2 per 1000 measles cases); however, measles vaccination cannot cause death if contraindications are considered. Febrile seizures happen in about 1 in 3000 vaccinees, but do not have consequences. It could not be shown that a licensed measles vaccine can cause encephalitis. Adverse events caused by immunization are known as well as complications of the disease averted by immunization.
Background morbidity like headaches, fever or rare cases of invagination [
63,
64] will happen in a certain percentage of the population regardless of whether a medicinal product is administered. It was found that during 1 year, one fifth of the population (20.1%) experiences an episode of headache [
63].
In order to correctly distinguish between a causal adverse event of immunization or a coincidental acausal event, it is necessary to know the background morbidity of the population [
65].
By adding adjuvants such as aluminium salts, the antigen concentration in vaccines can be reduced as well as the number of required doses in the vaccination schedule [
66]. This may be important in increasing the supply of vaccines in new global influenza pandemics.
Aluminium salts are added to vaccines in different formulations such as Al hydroxide, Al hydroxyphosphate, Al phosphate, or Al potassium sulfate. The Al adjuvants are nearly insoluble, and parts may remain as depot in the muscle. Adjuvants are excreted via the kidneys. As it is considered to be effective and safe, vaccines against tetanus, hepatitis A, hepatitis B, human papillomavirus and
Haemophilus influenzae b include aluminium salts [
67]. In Europe, the maximum aluminium amount (calculated as Al
3+) in one vaccine dose is 1.25 mg, which is significantly less than our aluminium intake through diet or water intake, even if less than 1% of the oral burden is absorbed by the body. In reality the possible maximum aluminium concentration in vaccines is not achieved. Although high aluminium doses can be toxic (concentration maximum in food 2 mg/kg BW per day), there is no evidence supporting teratogenicity or carcinogenicity [
66]. There is no difference when comparing aluminium levels of vaccinated subjects with unvaccinated individuals owing to the small quantity of aluminium contained in vaccines [
67].
It is important to keep in mind that aluminium salts are frost-sensitive, meaning that at freezing temperatures, aluminium salts can lead to diminished immunogenicity and also to an increase in adverse local reactions. Frozen adjuvanted vaccines must be discarded.
Ethylmercury, also referred to as thiomersal, was added to vaccines as a preservative in multidose containers. [
68]. But with the availability of single-dose containers or ready to use syringes, the addition of a preservative was no longer necessary. The fact is that all vaccines for children have been free of thiomersal as preservative since 2000, with the exception of some brands of H1N1 pandemic influenza vaccine in 2009/2010. In Austria, only a preservative-free H1N1 vaccine was used in a 10-dose container during the pandemic. Since live vaccines must not contain a preservative, but are widely used in 10-dose containers, it is questionable whether preservatives are in general necessary in vaccines. In some vaccines thiomersal was also used for inactivation of the antigen. This residue of production remained in some vaccines at less than 1% of the concentration of thiomersal used as a preservative until 2008; however, some anti-vaxers still believe in its toxicity in vaccines, although this topic has been rebutted repeatedly.
Since 1999, the use of thiomersal-containing vaccines has been decreasing worldwide, while the prevalence of autism spectrum disorders is rising. There is no contraindication for the use of thiomersal-containing vaccines in infants, children and non-pregnant women [
69]; however, thiomersal is not necessary in single-dose containers (ready to use syringes), when GMP are established.
Historically, the extensive and consistent vaccination campaigns against smallpox led to complete eradication of the virus in 1980—since then smallpox is dead. [
70,
71]. This was possible since the smallpox virus has only one reservoir—humans [
72]. Therefore, eradicating pathogens which have more than one host, for example the influenza virus [
73], is not possible.
The next disease to have pre-eradication status is polio. Too low vaccination rates in Pakistan and Afghanistan are still enabling the polio virus to spread and caused 20 symptomatic cases of polio in 2016 [
74], which increased to 69 reported cases as of August 2019 [
75].
It was shown in Israel in 2013 that in sewage 136 samples were positive for poliomyelitis virus, but no infections were found in the population due to high vaccine coverage [
76].
Despite the apparent difficulty of poliomyelitis eradication, it has already been proven that via resolution and extensive international collaboration this task is not a utopic experiment but rather a highly challenging yet achievable goal. The proof of principle that poliomyelitis can be eradicated is documented by the disappearance of poliomyelitis type 2 globally, with the last wild-type isolated in 1999.
Global eradication is technically possible for any pathogen that is restricted to replicate or reproduce only in humans; however, this theory has one serious constraint in its feasibility. In order to effectively eliminate any pathogen restricted to a human reservoir, it is crucial to get vaccination coverage as high as possible [
77]—the fewer unvaccinated people in a community, the less chance for the pathogen to spread from person to person.
There are always individuals who are too young to be vaccinated or cannot be vaccinated due to clinical reasons, such as underlying medical conditions like HIV infection, leukemia, ongoing chemotherapy, congenital disorders of the immune system or a history of severe reactions against the vaccine in question [
78].
Since these individuals cannot get vaccinated and, in many cases, already have to cope with an impaired immune system, they strongly rely on the immune community around them. This concept can be subsumed under the term herd immunity [
79,
80].
Therefore, non-medically exempt people refusing to vaccinate can benefit from reduced infectious pressure or herd immunity [
81] while at the same time weaken the overall security for those who need to be protected due to the resultant gaps in immunization barriers [
82]. Besides the protection of the defenseless non-vaccinable minority, the second pivotal aspect of achieving a high vaccination rate is the possibility of eradicating the pathogen in question, a subject that has already been addressed.
Like the smallpox vaccine regimen, vaccination programs against other organisms replicating solely in humans can be abandoned once this goal is achieved. A prominent example of a human-specific pathogen is the measles virus. Since the measles virus exhibits a high rate of replication [
77] and is highly contagious [
79,
82], an especially high vaccination coverage is required to regionally eliminate and later eradicate the disease [
83]. According to the WHO, 95% of the non-immune population needs to be vaccinated twice against measles to completely stop it from spreading [
78]; however, eliminating the virus in just one country and subsequently pausing the vaccination program will not suffice since it would just need one contagious person visiting from a country where the virus has not been eliminated to set off the next measles outbreak if the person was in contact with an unvaccinated individual. To effectively eradicate a human-specific pathogen like the measles virus, worldwide cooperation is needed. Lastly, another obvious yet decisive aspect of vaccinating against diseases like the measles virus is reducing the chance of contracting the disease and any of its entailing complications and keeping secondary risks to a minimum [
77]. Thus, vaccinating as many individuals as possible, given that there are no contraindications, maximizes the chances of pathogen eradication and, subsequently nullifies the need for vaccinating against the pathogen in question, as well as minimizing the risks of catching serious vaccine-preventable diseases.
The old whole cell pertussis vaccine contained all carbohydrates, DNA, RNA of a pertussis bacteria, and about 3000 proteins. The smallpox vaccine was a whole virus vaccine; smallpox virus is a huge virus with 200 proteins. A hexavalent vaccine against diphtheria, tetanus, pertussis, poliomyelitis,
Haemophilus influenza b and hepatitis B infections contains about 23 proteins as antigens. Various brands are licensed. See Table
1.
Table 1
Nr of Immunogenic Proteins and Polysaccharides Contained in Vaccines (adapted according to Offit [
84])
Smallpox | ≈200 | Smallpox | ≈200 | Diphtheria | 1 | DTaP | 5 |
Total | ≈200 | Diphtheria | 1 | Tetanus | 1 | Human Papilloma Virus | 4–9 |
– | Tetanus | 1 | Whole cell Pertussis | ≈3000 | Rotavirus | 65 |
– | Whole cell Pertussis | ≈3000 | Polio | 15 | Polio | 15 |
– | Polio | 15 | Measles | 10 | MMR | 24 |
– | Tuberculosis | 4000 | Mumps | 9 | Men C | 2 |
– | Total | ≈7217 | Rubella | 5 | HIB | 2 |
– | Total | ≈3041 | VZV | 69 |
– | Pneumococcus | 10–23 |
– | Hepatitis B virus | 1 |
– | Influenza | 6–33 |
– | Total | 203–248 |
If one looks at the biological diversity on a childrens playground, 1g of earth contains between 6400 and 38,000 bacterial species (excluding the number of viruses). Since one bacterial species has about 3000 proteins potentially acting as antigens, this amounts to a total of 19.2–114 million antigens [
83]. This huge number does not overwhelm our immune system if earth is swallowed or contaminates a small wound. In the 1960s recommended vaccines had a burden of over 7000 antigens, with the BCG vaccine containing about 4000 antigens, administered in the first week of life. Today all generally recommended vaccines have approximately the same number of antigens as were contained in the smallpox vaccine (200 antigens), but we can protect our children from many more infectious diseases.